Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
Clinical trial NCT04952571 · TERMINATED
Trial details
- NCT number
- NCT04952571
- Sponsor
- Beijing Sanbo Brain Hospital
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-27
- Primary completion
- 2022-12-31
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.